SANOFI (SAN.PA)       86.48  -1.71 (-1.94%)

86.48  -1.71 (-1.94%)

FR0000120578 - Common Stock


Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SAN. SAN was compared to 20 industry peers in the Pharmaceuticals industry. SAN has a bad profitability rating. Also its financial health evaluation is rather negative. SAN has a correct valuation and a medium growth rate.

Note: SAN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

SAN's Profit Margin of 16.43% is amongst the best of the industry. SAN does better than the industry average Profit Margin of 9.43%.

SAN has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for SAN.
VS Industry

Profit Margin (16.43%) VS Industry: 66% outperformed.

-1,195.28
43.54

Valuation

Valuation Rating

6

With a Price/Earnings Ratio of 10.92, the valuation of SAN can be described as very reasonable.
With a Forward Price/Earnings Ratio of 10.18, the valuation of SAN can be described as very reasonable.
SAN's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

SAN's Price/Earning Ratio is in line with the industry average which is at 12.30.
When comparing the Enterprise Value to EBITDA ratio of SAN to the average industry ratio of 7.56, SAN is valued more expensive than its industry peers.
VS Industry

Price/Earnings (10.92) VS Industry: 58% outperformed.

854.50
7.05

Enterprise Value/ EBITDA (10.92) VS Industry: 33% outperformed.

31.44
2.72

Growth

Growth Rating

6

The Earnings Per Share has grown by an impressive 23.94% over the past year.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Revenue has grown by 13.92% in the past year. This is quite good.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

Measured over the past 5 years, SAN shows a small growth in Earnings Per Share. The EPS has been growing by 2.87% on average per year.
The Earnings Per Share is expected to grow by 8.83% on average over the next 5 years.
The Revenue has been growing slightly by 2.46% on average over the past 5 years.
Based on estimates for the next 5 years, SAN will show a small growth in Revenue. The Revenue will grow by 4.70% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS2.87% 6.19% 23.94% 24.49% 13.9% 11.48% 8.83%
Revenue2.46% 3.17% 13.92% 13.01% 8.73% 7.33% 4.7%

Health

Health Rating

0

SAN has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for SAN.

VS Industry

Dividend

Dividend Rating

6

Compared to an average industry Dividend Yield of 3.32, SAN pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.47, SAN pays a better dividend.
The dividend of SAN is growing, but earnings are growing more, so the dividend growth is sustainable.

SAN has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
The dividend of SAN has a limited annual growth rate of 2.57%.
VS Industry

Dividend Yield (3.85%) VS Industry: 77% outperformed.

1.05
7.31
SAN Daily chart

SANOFI86.48

EPA:SAN (11/30/2022, 7:00:00 PM)-1.71 (-1.94%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 219.22B Analysts 79.39
Valuation
PE 10.92 Fwd PE 10.18
PEG (NY) 0.45 PEG (5Y) 3.81
P/S 3.36 P/B N/A
EV/EBITDA 10.92
Dividend
Dividend Yield 3.85% Dividend Growth 2.57%
DP N/A Ex-Date N/A
Growth
EPS 1Y 23.94% EPS 3Y 6.19%
EPS 5Y 2.87% EPS growth Q2Q 31.65%
EPS Next Y 24.49% EPS Next 2Y 13.9%
EPS Next 3Y 11.48% EPS Next 5Y 8.83%
Revenue growth 1Y 13.92% Revenue growth 3Y 3.17%
Revenue growth 5Y 2.46% Revenue growth Q2Q 21.32%
Revenue Next Year 13.01% Revenue Next 2Y 8.73%
Revenue Next 3Y 7.33% Revenue Next 5Y 4.7%
Health
Current Ratio N/A Quick Ratio N/A
Altman-Z N/A F-Score 1
Debt/Equity N/A WACC 6.82%
ROIC/WACC N/A
Profitability
ROA N/A ROE N/A
ROICexgc N/A ROIC N/A
PM 16.43% OM 26.26%
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext